- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
What We're Reading: EHR Oversight; Medicaid Expansion and CRC; Arkansas Work Requirements
FDA Commissioner Scott Gottlieb, MD, called for stricter oversight of electronic health records (EHRs); Medicaid expansion in Kentucky has led to increases in screening, diagnoses, and survival of colorectal cancer (CRC); contradicting claims from some federal and state officials, the majority of beneficiaries who lost coverage for not complying with Arkansas’ Medicaid work requirements have not found employment.
Gottlieb Calls for Stricter Oversight of Electronic Health Records
FDA Commissioner Scott Gottlieb, MD, called for a more tailored approach for oversight of electronic health records (EHRs) in response to a report published this week that found the government has spent more than $36 billion over the past decade to switch doctors and hospitals over to digital records. During the same period, there were thousands of reported deaths, injuries, and near issues associated with EHRs, reported Kaiser Health News.
Medicaid Expansion Linked to Lower Colorectal Cancer Mortality
Medicaid expansion in Kentucky has led to a decreased risk of death from colorectal cancer, according to a study published in the Journal of the American College of Surgeons. Looking at patients diagnosed with the disease between January 2011 and December 2016, researchers found that implementation of Medicaid expansion resulted in a significant increase in screening, diagnoses, and overall survival of colorectal cancer.
Most Beneficiaries Who Lost Coverage Under Work Requirements Not Employed
Contradicting claims that the majority of beneficiaries who lost coverage for failing to comply with Arkansas’ Medicaid work requirements found jobs, a review of state data has found that the large majority of the 18,000 who lost coverage are unemployed. According to an analysis from the Center on Budget and Policy Priorities, 1981 beneficiaries have reported finding new work, meaning more than 16,000 have not found jobs.
FDA Approves bluebird bio's Lovo-Cel Gene Therapy for Sickle Cell Disease
December 10th 2023The decision was supported by efficacy data from 36 patients from the ongoing phase 1/2 HGB-206 trial (NCT02140554) and 2 patients in the phase 3 HGB-210 trial (NCT04293185). It was the second approval from FDA for a gene therapy for sickle cell disease.
Read More
Cellular Therapies in Lymphoma Bring Hope, but Optimizing Their Use Remains a Challenge
December 10th 2023Recent decades have seen marked improvements in hematological cancer outcomes and an expanded armamentarium of therapies, but novel treatments require updated strategies that are not always easy to fine-tune, according to presenters at the 2023 American Society of Hematology Annual Meeting and Exposition.
Read More
